Corbus Pharmaceuticals Begins First Human Trial of CRB-601 for Advanced Solid Tumors, Marking First Patient Dosed.

siRNA (small interfering RNA) drugs and ASO (antisense oligonucleotide) drugs, as the two pillars of the small nucleic acid therapeutics field.

Solu Therapeutics Reveals Favorable Preclinical Findings for STX-0712 in Treating Chronic Myelomonocytic and Acute Myeloid Leukemias at the ASH Conference.

Seismic Therapeutic Unveils Fresh Preclinical Efficacy Results for S-1117 in Preventive and Treatment Animal Models of Immune Thrombocytopenia at the 66th ASH Meeting.

Molecular Targeting Technologies, Inc. (MTTI) has released preclinical research findings for their proprietary 225Ac-EBTATE targeting SSTR2-positive neuroendocrine tumors (NET).

Merck Reports Phase 3 KEYLYNK-001 Study Achieves Main Goal of Progression-Free Survival in Advanced Ovarian Cancer Patients.

Molecular Partners Unveils Clinical Findings for MP0533 Study and Preclinical Insights on MP0621 at ASH 2024, Advancing Their Research Agenda.

C4 Therapeutics Reveals Phase 1 Trial Results of Cemsidomide at the ASH Annual Meeting, Highlighting Its Potential as a Leading IKZF1/3 Degrader.

Boosting Effectiveness and Security: CStone Unveils Recent Clinical Findings on CS5001 for Advanced Lymphoma at the 66th ASH Conference.

Innovent unveiled new findings from its Phase 1 trial of the novel anti-CLDN18.2 ADC (IBI343) for advanced pancreatic cancer at the ESMO Asia Congress 2024.

Merck's experimental drug Zilovertamab Vedotin combined with R-CHP achieved a complete response rate of 100% at a dosage of 1.75 mg/kg.

PureTech showcases LYT-200 (anti-galectin-9 monoclonal antibody) data for relapsed/refractory AML/MDS at the 2024 ASH Annual Meeting.